Clinical Trial Update: Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) [Phase 3]

View source ↗

Summary

Phase 3 cardiovascular outcomes trial of naltrexone SR/bupropion SR (Contrave) in overweight/obese subjects with cardiovascular risk factors was terminated; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CONTRAVE (bupropion/naltrexone)

Snippet

Sponsor: Orexigen Therapeutics, Inc | Conditions: Obesity, Overweight | Phase 3 | Status: TERMINATED | Results posted: 2017-02-27